Last updated: 11/04/2018 05:43:16
The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder
GSK study ID
BKB105190
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Standardization of Fluid Intake on the Variability of Measured Voiding Parameters in Female Patients with Idiopathic Overactive Bladder
Trial description: The purpose of this study is to determine if standardizing fluid intake in a clinic setting will reduce variability of individual voiding parameters and potentially serve as a way to limit patient exposure in the initial assessment of efficacy of compounds being developed for Overactive Bladder.
Primary purpose:
Diagnostic
Trial design:
Parallel Assignment
Masking:
Not applicable
Allocation:
Randomized
Primary outcomes:
Variability of change from baseline in mean volume per void measured on 3 consecutive days.
Timeframe: 3 consecutive days
Secondary outcomes:
Mean change from baseline in volume voided per void. Percent and actual change from baseline in maximum volume voided, number of micturitions, number of incontinence episodes, number of urgency episodes, and time to first void on 3 consecutive days.
Timeframe: 3 consecutive days
Interventions:
Drug: DETROL LA (drug)
Enrollment:
55
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Overactive Bladder
Product
solabegron
Collaborators
Not applicable
Study date(s)
August 2007 to January 2008
Type
Interventional
Phase
1
Participation criteria
Sex
Female
Age
18+ years
Accepts healthy volunteers
No
- Eligible participants will be females who are 18 years of age or older, with Overactive Bladder as evidenced by daily episodes of urgency without incontinence, which may be associated with frequency or nocturia but without bladder pain. At screening, eligible patients must report frequency, defined as at least 8 micturitions per 24 hour period.
- Eligible patients must have signed the informed consent and must meet all inclusion and exclusion criteria as determined during the screening visit.
- Any abnormality identified on the screening examination or any other medical condition or circumstance making the patient unsuitable for participation in the study based on the Investigator’s and Medical Monitor’s assessment
- Any contraindication to Detrol LA or other anti-muscarinic medications
Inclusion and exclusion criteria
Inclusion criteria:
- Eligible participants will be females who are 18 years of age or older, with Overactive Bladder as evidenced by daily episodes of urgency without incontinence, which may be associated with frequency or nocturia but without bladder pain. At screening, eligible patients must report frequency, defined as at least 8 micturitions per 24 hour period.
- Eligible patients must have signed the informed consent and must meet all inclusion and exclusion criteria as determined during the screening visit.
Exclusion criteria:
- Any contraindication to Detrol LA or other anti-muscarinic medications
- Inability to consume 10 cc/kg of fluid within 30 minutes
- Regular alcohol consumption averaging ³7 drinks/week for women (1 drink = 100mL of wine or 285mL of beer or 30mL of hard liquor)
- Positive urine drug or alcohol at screening at screening
- Average blood pressure measurements systolic ≥140 or diastolic ≥90 at screening at screening
- QTcB value ≥ 450 msec at screening
- Poorly-controlled diabetes mellitus or hypertension, as evidenced by a change in medication within the 2 months prior to initiation of the study
- History of urinary retention or gastric retention
- Known history of narrow-angle glaucoma
- History of QT prolongation
- Known reduction in hepatic or renal function
- Concomitant Use of loop diuretics (eg. Furosemide)
- Concomitant use of a medication that is a potent inhibitor of CYP3A4
- Class IA or Class III antiarrhythmic medications
- Patient is unable and/or unwilling to adhere to Lifestyle Guidelines
- For women of child bearing potential, a positive serum β-hCG at screening or pre-dose, or an unwillingness to agree to adequate contraception from the time of screening until the completion of the study:
- Positive for hepatitis C antibody, hepatitis B surface antigen or HIV at screening.
- Presence of urinary tract infection within 4 weeks of screening.
- Post-void residual of >150 mL (bladder ultrasound).
Any abnormality identified on the screening examination or any other medical condition or circumstance making the patient unsuitable for participation in the study based on the Investigator’s and Medical Monitor’s assessment
Trial location(s)
Location
GSK Investigational Site
Randwick, Sydney, New South Wales, Australia, 2031
Status
Study Complete
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2008-04-01
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website